US pharma company Forest Laboratories has agreed to buy Clinical Data for $30 (£19) per share in cash, equivalent to $1.2 billion, plus $6 per share payable if Viibryd (vilazodone) reaches commercial milestones. Forest intends to use existing cash to finance the deal. Viibryd was approved in January in the ...